Literature DB >> 23340173

Functional analysis of the two reciprocal fusion genes MLL-NEBL and NEBL-MLL reveal their oncogenic potential.

Mariana Emerenciano1, Eric Kowarz, Katharina Karl, Bruno de Almeida Lopes, Bastian Scholz, Silvia Bracharz, Claus Meyer, Maria S Pombo-de-Oliveira, Rolf Marschalek.   

Abstract

MLL gene aberrations are frequently diagnosed in infant acute myeloid leukemia (AML). We previously described the MLL-NEBL and NEBL-MLL genomic fusions in an infant AML patient with a chromosomal translocation t(10;11)(p12;q23). NEBL was the second Nebulin family member (LASP1, NEBL) which was found to be involved in MLL rearrangements. Here, we report on our attempts to unravel the oncogenic properties of both fusion genes. First, RT-PCR analyses revealed the presence of the MLL-NEBL and NEBL-MLL mRNAs in the diagnostic sample of the patient. Next, expression cassettes for MLL-NEBL and NEBL-MLL were cloned into a sleeping beauty vector backbone. After stable transfection, the biological effects of MLL-NEBL, NEBL-MLL or the combination of both fusion proteins were investigated in a conditional cell culture model. NEBL-MLL but also co-transfected cells displayed significantly higher growth rates according to the data obtained by cell proliferation assay. The focus formation experiments revealed differences in the shape and number of colonies when comparing MLL-NEBL, NEBL-MLL- and co-transfected cells. The results obtained in this study suggest that the reciprocal fusion genes of the Nebulin gene family might be of biological importance.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23340173     DOI: 10.1016/j.canlet.2012.12.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

Review 1.  Sleeping Beauty transposon system for genetic etiological research and gene therapy of cancers.

Authors:  Xiaomei Hou; Yan Du; Yang Deng; Jianfeng Wu; Guangwen Cao
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

Review 2.  Mouse models of MLL leukemia: recapitulating the human disease.

Authors:  Thomas A Milne
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

3.  The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.

Authors:  Dagmar Schinnerl; Klaus Fortschegger; Maximilian Kauer; João R M Marchante; Reinhard Kofler; Monique L Den Boer; Sabine Strehl
Journal:  Blood       Date:  2014-12-16       Impact factor: 22.113

4.  Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias.

Authors:  Bruno A Lopes; Caroline Pires Poubel; Cristiane Esteves Teixeira; Aurélie Caye-Eude; Hélène Cavé; Claus Meyer; Rolf Marschalek; Mariana Boroni; Mariana Emerenciano
Journal:  Front Pharmacol       Date:  2022-06-06       Impact factor: 5.988

5.  Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.

Authors:  Nilda L Alicea-Velázquez; Stephen A Shinsky; Daniel M Loh; Jeong-Heon Lee; David G Skalnik; Michael S Cosgrove
Journal:  J Biol Chem       Date:  2016-08-25       Impact factor: 5.157

6.  MLL-SEPT5 Fusion Transcript in Two de novo Acute Myeloid Leukemia Patients With t(11;22)(q23;q11).

Authors:  Nana Wang; Xiaojin Wu; Guangying Sheng; Liang Ma; Lijun Wen; Hong Yao; Suning Chen
Journal:  Ann Lab Med       Date:  2016-09       Impact factor: 3.464

7.  The MLL recombinome of acute leukemias in 2013.

Authors:  C Meyer; J Hofmann; T Burmeister; D Gröger; T S Park; M Emerenciano; M Pombo de Oliveira; A Renneville; P Villarese; E Macintyre; H Cavé; E Clappier; K Mass-Malo; J Zuna; J Trka; E De Braekeleer; M De Braekeleer; S H Oh; G Tsaur; L Fechina; V H J van der Velden; J J M van Dongen; E Delabesse; R Binato; M L M Silva; A Kustanovich; O Aleinikova; M H Harris; T Lund-Aho; V Juvonen; O Heidenreich; J Vormoor; W W L Choi; M Jarosova; A Kolenova; C Bueno; P Menendez; S Wehner; C Eckert; P Talmant; S Tondeur; E Lippert; E Launay; C Henry; P Ballerini; H Lapillone; M B Callanan; J M Cayuela; C Herbaux; G Cazzaniga; P M Kakadiya; S Bohlander; M Ahlmann; J R Choi; P Gameiro; D S Lee; J Krauter; P Cornillet-Lefebvre; G Te Kronnie; B W Schäfer; S Kubetzko; C N Alonso; U zur Stadt; R Sutton; N C Venn; S Izraeli; L Trakhtenbrot; H O Madsen; P Archer; J Hancock; N Cerveira; M R Teixeira; L Lo Nigro; A Möricke; M Stanulla; M Schrappe; L Sedék; T Szczepański; C M Zwaan; E A Coenen; M M van den Heuvel-Eibrink; S Strehl; M Dworzak; R Panzer-Grümayer; T Dingermann; T Klingebiel; R Marschalek
Journal:  Leukemia       Date:  2013-04-30       Impact factor: 11.528

8.  Molecular studies reveal MLL-MLLT10/AF10 and ARID5B-MLL gene fusions displaced in a case of infantile acute lymphoblastic leukemia with complex karyotype.

Authors:  Mitsuteru Hiwatari; Masafumi Seki; Shogo Akahoshi; Kenichi Yoshida; Satoru Miyano; Yuichi Shiraishi; Hiroko Tanaka; Kenichi Chiba; Seishi Ogawa; Junko Takita
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

9.  HOTTIP Enhances Gemcitabine and Cisplatin Resistance Through Sponging miR-637 in Cholangiocarcinoma.

Authors:  Kun Gao; Shuhua Chen; Xiangyu Yang
Journal:  Front Oncol       Date:  2021-07-05       Impact factor: 6.244

Review 10.  Systematic Classification of Mixed-Lineage Leukemia Fusion Partners Predicts Additional Cancer Pathways.

Authors:  Rolf Marschalek
Journal:  Ann Lab Med       Date:  2016-03       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.